Saudi Journal of Kidney Diseases and Transplantation

BRIEF COMMUNICATION
Year
: 2016  |  Volume : 27  |  Issue : 2  |  Page : 335--340

Outcome of patients with multiple myeloma and renal failure on novel regimens


Tayebeh Soleymanian1, Adel Soleimani1, Asadollah Musavi2, Kourosh Mojtahedi1, Gholamreza Hamid1 
1 Nephrology Department, Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran
2 Hematologic and Oncologic Research Institute, Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran

Correspondence Address:
Tayebeh Soleymanian
Nephrology Department, Shariati Hospital, Tehran University of Medical Sciences, Tehran
Iran

Renal involvement occurs in 20-40% of newly diagnosed multiple myeloma (MM) patients, and diagnosis of myeloma is frequently made after investigation for unexplained renal disease. This is a retrospective study between 2006 and 2013 in which 57 consecutive patients seen at the Nephrology Unit with diagnosis of MM were enrolled. MM was diagnosed for the first time because of renal dysfunction and/or proteinuria in these patients. The mean age of the patients (65% male) was 58.3 ± 12.7 years. The median baseline serum creatinine was 3.5 mg/dL (1.4-14.5). Anemia (hemoglobin <12 g/dL) was noted in 88% and hypercalcemia (calcium >10.5 mg/dL) in 35% of patients. Early hemodialysis was started in 28 patients (49%). Thalidomide plus dexamethasone (16% on bortezomib) were the main therapeutic regimens. Three patients (5%) underwent autologous stem cell transplantation. Twenty-six patients (45.6%) died during a median follow-up of 25 months (1-90). The mean age of patients who died was significantly higher than the age in patients who were alive (62.2 ± 12.7 vs. 55.2 ± 11.9 years, respectively; P = 0.037). Early hemodialysis had no significant effect on mortality rate. The one-, threeand fiveyear patient survival was 71%, 54%, and 41%, respectively. The median overall survival of patients was 50 months. Prolonged patient survival can be expected in myeloma patients with renal failure or on dialysis by applying novel therapeutic agents.


How to cite this article:
Soleymanian T, Soleimani A, Musavi A, Mojtahedi K, Hamid G. Outcome of patients with multiple myeloma and renal failure on novel regimens.Saudi J Kidney Dis Transpl 2016;27:335-340


How to cite this URL:
Soleymanian T, Soleimani A, Musavi A, Mojtahedi K, Hamid G. Outcome of patients with multiple myeloma and renal failure on novel regimens. Saudi J Kidney Dis Transpl [serial online] 2016 [cited 2020 Apr 7 ];27:335-340
Available from: http://www.sjkdt.org/article.asp?issn=1319-2442;year=2016;volume=27;issue=2;spage=335;epage=340;aulast=Soleymanian;type=0